Heme oxygenase-1 (HO-1) catalyses the degradation of heme to biliverdin, free iron, and carbon monoxide. The promoter region contains a highly polymorphic (GT)_n repeat, where shorter (GT)_n repeat sequences are linked to higher transcriptional activity, which was shown to correlate with a cytoprotective effect. Higher HO-1 levels may protect from cardiac allograft vasculopathy. Cardiac allograft recipients transplanted between 1988 and 2012 were analyzed for the HO-1 (GT)_n repeat polymorphism using PCR and DNA fragment analysis with capillary electrophoresis. A relation to cardiac allograft vasculopathy (CAV) was analyzed using Cox regression including common risk factors for CAV and the occurrence of rejection episodes as explanatory variables. A total of 344 patients were analyzed, of which 127 patients were positive for CAV (36.9%). In our multivariable Cox regression analysis, the short homozygous HO-1 (GT)_n genotype with <27 repeats (S/S) revealed a higher risk for CAV (P = 0.032). Donor age (P = 0.001) and donor weight (P = 0.005) were significant predictors for CAV. A potential risk for CAV was associated with rejection episodes (P = 0.058) and history of smoking (P = 0.06). The recipient HO-1 (GT)_n genotype may contribute to CAV development. This finding has to be evaluated in larger series including studies targeting the underlying disease mechanism.

References

1Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 1996; 2: 87.
10.1038/nm0196-87
CAS PubMed Web of Science® Google Scholar
2Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004; 37: 1097.
10.1016/j.freeradbiomed.2004.07.008
CAS PubMed Web of Science® Google Scholar
3Linnenbaum M, Busker M, Kraehling JR, Behrends S. Heme oxygenase isoforms differ in their subcellular trafficking during hypoxia and are differentially modulated by cytochrome P450 reductase. PLoS One 2012; 7: e35483.
10.1371/journal.pone.0035483
CAS PubMed Web of Science® Google Scholar
4Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79.
10.1124/pr.107.07104
CAS PubMed Web of Science® Google Scholar
5Kimpara T, Takeda A, Watanabe K, et al. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet 1997; 100: 145.
10.1007/s004390050480
CAS PubMed Web of Science® Google Scholar
6Shibahara S, Sato M, Muller RM, Yoshida T. Structural organization of the human heme oxygenase gene and the function of its promoter. Eur J Biochem 1989; 179: 557.
10.1111/j.1432-1033.1989.tb14583.x
CAS PubMed Web of Science® Google Scholar
7Chen YH, Lin SJ, Lin MW, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002; 111: 1.
10.1007/s00439-002-0769-4
CAS PubMed Web of Science® Google Scholar
8Yamada N, Yamaya M, Okinaga S, et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000; 66: 187.
10.1086/302729
CAS PubMed Web of Science® Google Scholar
9Endler G, Exner M, Schillinger M, et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. Thromb Haemost 2004; 91: 155.
10.1160/TH03-05-0291
CAS PubMed Web of Science® Google Scholar
10Han SW, Song W, Kim HS, et al. HMOX1 gene promoter polymorphism is not associated with coronary artery disease in Koreans. Ann Lab Med 2014; 34: 337.
10.3343/alm.2014.34.5.337
CAS PubMed Web of Science® Google Scholar
11Tiroch K, Koch W, von Beckerath N, Kastrati A, Schomig A. Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. Eur Heart J 2007; 28: 968.
10.1093/eurheartj/ehm036
CAS PubMed Web of Science® Google Scholar
12Kaneda H, Ohno M, Taguchi J, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002; 22: 1680.
10.1161/01.ATV.0000033515.96747.6F
CAS PubMed Web of Science® Google Scholar
13Schillinger M, Exner M, Minar E, et al. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol 2004; 43: 950.
10.1016/j.jacc.2003.09.058
CAS PubMed Web of Science® Google Scholar
14Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 2006; 99: 801.
10.1161/01.RES.0000246086.93555.f3
CAS PubMed Web of Science® Google Scholar
15Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report – 2012. J Heart Lung Transplant 2012; 31: 1052.
10.1016/j.healun.2012.08.002
PubMed Web of Science® Google Scholar
16Colvin-Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transplant 2011; 25: 175.
10.1111/j.1399-0012.2010.01307.x
PubMed Web of Science® Google Scholar
17Pollack A, Nazif T, Mancini D, Weisz G. Detection and imaging of cardiac allograft vasculopathy. JACC Cardiovasc Imaging 2013; 6: 613.
10.1016/j.jcmg.2013.03.001
PubMed Web of Science® Google Scholar
18Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008; 117: 2131.
10.1161/CIRCULATIONAHA.107.711911
PubMed Web of Science® Google Scholar
19Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29: 717.
10.1016/j.healun.2010.05.017
PubMed Web of Science® Google Scholar
20Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
10.1016/j.healun.2005.03.019
PubMed Web of Science® Google Scholar
21Doberer D, Haschemi A, Andreas M, et al. Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects. Br J Pharmacol 2010; 161: 1751.
10.1111/j.1476-5381.2010.00990.x
CAS PubMed Web of Science® Google Scholar
22Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343.
10.1016/0197-2456(96)00075-X
CAS PubMed Web of Science® Google Scholar
23Holweg CT, Balk AH, Uitterlinden AG, et al. Functional heme oxygenase-1 promoter polymorphism in relation to heart failure and cardiac transplantation. J Heart Lung Transplant 2005; 24: 493.
10.1016/j.healun.2004.02.010
PubMed Web of Science® Google Scholar
24Ullrich R, Exner M, Schillinger M, et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter and cardiac allograft vasculopathy. J Heart Lung Transplant 2005; 24: 1600.
10.1016/j.healun.2004.11.009
PubMed Web of Science® Google Scholar
25Bouche D, Chauveau C, Roussel JC, et al. Inhibition of graft arteriosclerosis development in rat aortas following heme oxygenase-1 gene transfer. Transpl Immunol 2002; 9: 235.
10.1016/S0966-3274(02)00037-0
CAS PubMed Web of Science® Google Scholar
26Du D, Chang S, Chen B, Zhou H, Chen ZK. Adenovirus-mediated heme oxygenase transfer inhibits graft arteriosclerosis in rat aortic transplants. Transplant Proc 2007; 39: 3446.
10.1016/j.transproceed.2007.03.114
CAS PubMed Web of Science® Google Scholar
27Chen M, Zhou L, Ding H, et al. Short (GT) (n) repeats in heme oxygenase-1 gene promoter are associated with lower risk of coronary heart disease in subjects with high levels of oxidative stress. Cell Stress Chaperones 2012; 17: 329.
10.1007/s12192-011-0309-z
CAS PubMed Web of Science® Google Scholar
28Chen YH, Chau LY, Chen JW, Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008; 31: 1615.
10.2337/dc07-2126
CAS PubMed Web of Science® Google Scholar
29White M, Cantin B, Haddad H, et al. Cardiac signaling molecules and plasma biomarkers after cardiac transplantation: impact of tacrolimus versus cyclosporine. J Heart Lung Transplant 2013; 32: 1222.
10.1016/j.healun.2013.09.010
PubMed Web of Science® Google Scholar
30Jais A, Einwallner E, Sharif O, et al. Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell 2014; 158: 25.
10.1016/j.cell.2014.04.043
CAS PubMed Web of Science® Google Scholar
31Araujo JA, Zhang M, Yin F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol 2012; 3: 119.
10.3389/fphar.2012.00119
PubMed Web of Science® Google Scholar
32Durante W. Targeting heme oxygenase-1 in vascular disease. Curr Drug Targets 2010; 11: 1504.
10.2174/1389450111009011504
CAS PubMed Web of Science® Google Scholar
33Li W, Iyer S, Lu L, et al. Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. Transpl Int 2003; 16: 849.
10.1111/j.1432-2277.2003.tb00253.x
CAS PubMed Web of Science® Google Scholar
34Soares MP, Lin Y, Anrather J, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998; 4: 1073.
10.1038/2063
CAS PubMed Web of Science® Google Scholar
35Braudeau C, Bouchet D, Tesson L, et al. Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer. Gene Ther 2004; 11: 701.
10.1038/sj.gt.3302208
CAS PubMed Web of Science® Google Scholar
36Evans JM, Navarro S, Doki T, Stewart JM, Mitsuhashi N, Kearns-Jonker M. Gene transfer of heme oxygenase-1 using an adeno-associated virus serotype 6 vector prolongs cardiac allograft survival. J Transplant 2012; 2012: 740653.
10.1155/2012/740653
CAS PubMed Google Scholar
37Tsui TY, Wu X, Lau CK, et al. Prevention of chronic deterioration of heart allograft by recombinant adeno-associated virus-mediated heme oxygenase-1 gene transfer. Circulation 2003; 107: 2623.
CAS PubMed Web of Science® Google Scholar
38Woo J, Iyer S, Cornejo MC, et al. Stress protein-induced immunosuppression: inhibition of cellular immune effector functions following overexpression of haem oxygenase (HSP 32). Transpl Immunol 1998; 6: 84.
10.1016/S0966-3274(98)80022-1
CAS PubMed Web of Science® Google Scholar
39Ono K, Goto Y, Takagi S, et al. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis 2004; 173: 315.
10.1016/j.atherosclerosis.2003.11.021
CAS PubMed Web of Science® Google Scholar
40Lublinghoff N, Winkler K, Winkelmann BR, et al. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med Genet 2009; 10: 36.
10.1186/1471-2350-10-36
CAS PubMed Web of Science® Google Scholar
41Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069.
10.1161/01.CIR.96.6.2069
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume30, Issue5

May 2017

Pages 510-518

The recipient's heme oxygenase-1 promoter region polymorphism is associated with cardiac allograft vasculopathy

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The recipient's heme oxygenase-1 promoter region polymorphism is associated with cardiac allograft vasculopathy

Summary

References

Citing Literature

References

Related

Information